Pharma Mar (PHMMF) Projected to Post Quarterly Earnings on Thursday

Pharma Mar (OTCMKTS:PHMMF) is expected to announce its resultson Thursday, April 23rd. Analysts expect the company to announce earnings of $0.2789 per share and revenue of $43.1330 million for the quarter.

Pharma Mar Price Performance

Shares of Pharma Mar stock opened at $106.48 on Tuesday. The company has a current ratio of 3.02, a quick ratio of 2.44 and a debt-to-equity ratio of 0.14. Pharma Mar has a 52-week low of $80.91 and a 52-week high of $110.40. The stock has a 50-day simple moving average of $93.59 and a 200-day simple moving average of $91.33.

Pharma Mar Company Profile

PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.

The company’s flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.